Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CL stock price vs LLY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LLY's multiple
Needs LLY P/E.
Implied fair value · at CL's multiple
Needs CL P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
COLGATE-PALMOLIVE COMPANY · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ELI LILLY AND COMPANY · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PROCTER & GAMBLE Co
CL vs PG
JOHNSON & JOHNSON
CL vs JNJ
CHURCH & DWIGHT CO INC /DE/
CL vs CHD
KIMBERLY CLARK CORP
CL vs KMB
EDGEWELL PERSONAL CARE Co
CL vs EPC
UNILEVER PLC
CL vs UL
Pfizer Inc.
CL vs PFE
Merck & Co., Inc.
CL vs MRK
AbbVie Inc.
CL vs ABBV
Amgen Inc.
CL vs AMGN
Bristol-Myers Squibb Company
CL vs BMY
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CL can sustain its current margin profile while improving growth and maintaining low distress risk, then the stock can be held or selectively accumulated because LLY-based P/E suggests upside; otherwise, the much weaker growth and profitability versus LLY argue for caution.
On a P/E basis, CL at 35.5x trades below LLY at 51.7x, which mechanically implies upside to the $135.88 LLY-based value versus the $93.27 current price. However, the market is assigning CL a much lower multiple for good reason: its growth and margin profile are materially weaker than LLY’s.
Supporting Metrics
